Hull, A.; Li, Y.; Bartholomeusz, D.; Hsieh, W.; Tieu, W.; Pukala, T.L.; Staudacher, A.H.; Bezak, E.
Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. Cells 2022, 11, 2983.
https://doi.org/10.3390/cells11192983
AMA Style
Hull A, Li Y, Bartholomeusz D, Hsieh W, Tieu W, Pukala TL, Staudacher AH, Bezak E.
Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. Cells. 2022; 11(19):2983.
https://doi.org/10.3390/cells11192983
Chicago/Turabian Style
Hull, Ashleigh, Yanrui Li, Dylan Bartholomeusz, William Hsieh, William Tieu, Tara L. Pukala, Alexander H. Staudacher, and Eva Bezak.
2022. "Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma" Cells 11, no. 19: 2983.
https://doi.org/10.3390/cells11192983
APA Style
Hull, A., Li, Y., Bartholomeusz, D., Hsieh, W., Tieu, W., Pukala, T. L., Staudacher, A. H., & Bezak, E.
(2022). Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. Cells, 11(19), 2983.
https://doi.org/10.3390/cells11192983